|
1
|
Verner JV and Morrison AB: Islet cell
tumor and a syndrome of refractory watery diarrhea and hypokalemia.
Am J Med. 25:374–380. 1958.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jensen RT, Cadiot G, Brandi ML, de Herder
WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A and
Kianmanesh R: Barcelona Consensus Conference participants: ENETS
consensus guidelines for the management of patients with digestive
neuroendocrine neoplasms: Functional pancreatic endocrine tumor
syndromes. Neuroendocrinology. 95:98–119. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yao JC, Eisner MP, Leary C, Dagohoy C,
Phan A, Rashid A, Hassan M and Evans DB: Population-based study of
islet cell carcinoma. Ann Surg Oncol. 14:3492–3500. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Parbhu SK and Adler DG: Pancreatic
neuroendocrine tumors: Contemporary diagnosis and management. Hosp
Pract 1995. 44:109–119. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Long RG, Bryant MG, Mitchell SJ, Adrian
TE, Polak JM and Bloom SR: Clinicopathological study of pancreatic
and ganglioneuroblastoma tumours secreting vasoactive intestinal
polypeptide (vipomas). Br Med J (Clin Res Ed). 282:1767–1771.
1981.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Belei OA, Heredea ER, Boeriu E, Marcovici
TM, Cerbu S, Mărginean O, Iacob ER, Iacob D, Motoc AGM and Boia ES:
Verner-Morrison syndrome. Literature review. Rom J Morphol Embryol.
58:371–376. 2017.PubMed/NCBI
|
|
7
|
Chen Y, Shi D, Dong F, Han SG, Qian ZH,
Yang LI, Wang Y, Yu RS, Li QH and Fu YB: Multiple-phase spiral CT
findings of pancreatic vasoactive intestinal peptide-secreting
tumor: A case report. Oncol Lett. 10:2351–2354. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Krejs GJ: VIPoma syndrome. Am J Med.
82:37–48. 1987.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ghaferi AA, Chojnacki KA, Long WD, Cameron
JL and Yeo CJ: Pancreatic VIPomas: Subject review and one
institutional experience. J Gastrointest Surg. 12:382–393.
2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Said SI and Mutt V: Polypeptide with broad
biological activity: Isolation from small intestine. Science.
169:1217–1218. 1970.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Friesen SR: Update on the diagnosis and
treatment of rare neuroendocrine tumors. Surg Clin North Am.
67:379–393. 1987.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Schizas D, Mastoraki A, Bagias G, Patras
R, Moris D, Lazaridis II, Arkadopoulos N and Felekouras E:
Clinicopathological data and treatment modalities for pancreatic
vipomas: A systematic review. J BUON. 24:415–423. 2019.PubMed/NCBI
|
|
13
|
Murphy MS, Sibal A and Mann JR: Persistent
diarrhoea and occult vipomas in children. BMJ. 320:1524–1526.
2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Brentjens R and Saltz L: Islet cell tumors
of the pancreas: The medical oncologist's perspective. Surg Clin
North Am. 81:527–542. 2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mekhjian HS and O'Dorisio TM: VIPoma
syndrome. Semin Oncol. 14:282–291. 1987.PubMed/NCBI
|
|
16
|
Remme CA, de Groot GH and Schrijver G:
Diagnosis and treatment of VIPoma in a female patient. Eur J
Gastroenterol Hepatol. 18:93–99. 2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Metz DC and Jensen RT: Gastrointestinal
neuroendocrine tumors: Pancreatic endocrine tumors.
Gastroenterology. 135:1469–1492. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Piet R, Dunckley H, Lee K and Herbison AE:
Vasoactive intestinal peptide excites GnRH neurons in male and
female mice. Endocrinology. 157:3621–3630. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Abu-Zaid A, Azzam A, Abudan Z, Algouhi A,
Almana H and Amin T: Sporadic pancreatic vasoactive intestinal
peptide-producing tumor (VIPoma) in a 47-year-old male. Hematol
Oncol Stem Cell Ther. 7:109–115. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen C, Zheng Z, Li B, Zhou L, Pang J, Wu
W, Zheng C and Zhao Y: Pancreatic VIPomas from China: Case reports
and literature review. Pancreatology. 19:44–49. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Anderson CW and Bennett JJ: Clinical
presentation and diagnosis of pancreatic neuroendocrine tumors.
Surg Oncol Clin N Am. 25:363–374. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Grozinsky-Glasberg S, Mazeh H and Gross
DJ: Clinical features of pancreatic neuroendocrine tumors. J
Hepatobiliary Pancreat Sci. 22:578–585. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Smith SL, Branton SA, Avino AJ, Martin JK,
Klingler PJ, Thompson GB, Grant CS and van Heerden JA: Vasoactive
intestinal polypeptide secreting islet cell tumors: A 15-year
experience and review of the literature. Surgery. 124:1050–1055.
1998.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nilubol N, Freedman EM, Quezado MM, Patel
D and Kebebew E: Pancreatic neuroendocrine tumor secreting
vasoactive intestinal peptide and dopamine with pulmonary emboli: A
case report. J Clin Endocrinol Metab. 101:3564–3567.
2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pasricha G, Padhi P, Daboul N and Monga
DK: Management of well-differentiated gastroenteropancreatic
neuroendocrine tumors (GEPNETs): A review. Clin Ther. 39:2146–2157.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Debray MP, Geoffroy O, Laissy JP, Lebtahi
R, Silbermann-Hoffman O, Henry-Feugeas MC, Cadiot G, Mignon M and
Schouman-Claeys E: Imaging appearances of metastases from
neuroendocrine tumours of the pancreas. Br J Radiol. 74:1065–1070.
2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Semelka RC, Custodio CM, Cem Balci N and
Woosley JT: Neuroendocrine tumors of the pancreas: Spectrum of
appearances on MRI. J Magn Reson Imaging. 11:141–148.
2000.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lam S, Liew H, Khor HT, Dalan R, Kon YC,
Jong M, Chew DE and Leow MK: VIPoma in a 37-year-old man. Lancet.
382(832)2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ram R, Natanzi N, Saadat P, Eliav D and
Vadmal MS: Skin metastasis of pancreatic vasoactive intestinal
polypeptide tumor: Case report and review of the literature. Arch
Dermatol. 142:946–947. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
O'Dorisio TM, Mekhjian HS and Gaginella
TS: Medical therapy of VIPomas. Endocrinol Metab Clin North Am.
18:545–556. 1989.PubMed/NCBI
|
|
31
|
Ito T, Igarashi H, Uehara H and Jensen RT:
Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin
Pharmacother. 14:307–321. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Jensen RT, Niederle B, Mitry E, Ramage JK,
Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D,
et al: Frascati Consensus Conference; European neuroendocrine tumor
society: Gastrinoma (duodenal and pancreatic). Neuroendocrinology.
84:173–182. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhang X, Zhou L, Liu Y, Li W, Gao H, Wang
Y, Yao B, Jiang D and Hu P: Surgical resection of vasoactive
intestinal peptideoma with hepatic metastasis aids symptom
palliation: A case report. Exp Ther Med. 11:783–787.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Caplin ME, Pavel M, Ćwikła JB, Phan AT,
Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L,
et al: Lanreotide in metastatic enteropancreatic neuroendocrine
tumors. N Engl J Med. 371:224–233. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Plouin PF, Bertherat J, Chatellier G,
Billaud E, Azizi M, Grouzmann E and Epelbaum J: Short-term effects
of octreotide on blood pressure and plasma catecholamines and
neuropeptide Y levels in patients with phaeochromocytoma: A
placebo-controlled trial. Clin Endocrinol (Oxf). 42:289–294.
1995.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nguyen HN, Backes B, Lammert F, Wildberger
J, Winograd R, Busch N, Rieband H and Matern S: Long-term survival
after diagnosis of hepatic metastatic VIPoma: Report of two cases
with disparate courses and review of therapeutic options. Dig Dis
Sci. 44:1148–1155. 1999. View Article : Google Scholar
|
|
37
|
Lamberts SW, Pieters GF, Metselaar HJ, Ong
GL, Tan HS and Reubi JC: Development of resistance to a long-acting
somatostatin analogue during treatment of two patients with
metastatic endocrine pancreatic tumours. Acta Endocrinol (Copenh).
119:561–566. 1988.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Faiss S, Pape UF, Böhmig M, Dörffel Y,
Mansmann U, Golder W, Riecken EO and Wiedenmann B: International
Lanreotide and Interferon Alfa Study Group: Prospective,
randomized, multicenter trial on the antiproliferative effect of
lanreotide, interferon alfa, and their combination for therapy of
metastatic neuroendocrine gastroenteropancreatic tumors-the
International Lanreotide and Interferon Alfa Study Group. J Clin
Oncol. 21:2689–2696. 2003.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Lapeña Rodríguez M, Cholvi Calduch R,
Muñoz Forner E, Garcés Albir M and Sabater Ortí L: Life-threating
diarrhea and acute renal failure secondary to pancreatic VIPoma
treated by surgery. Rev Esp Enferm Dig. 111:641–643.
2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Dréanic J, Lepère C, El Hajjam M, Gouya H,
Rougier P and Coriat R: Emergency therapy for liver metastases from
advanced VIPoma: Surgery or transarterial chemoembolization? Ther
Adv Med Oncol. 8:383–387. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kos-Kudła B, Ćwikła J, Ruchała M,
Hubalewska-Dydejczyk A, Jarzab B, Krajewska J and Kamiński G:
Current treatment options for gastroenteropancreatic neuroendocrine
tumors with a focus on the role of lanreotide. Contemp Oncol
(Pozn). 21:115–122. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Shah M, Goldner W, Halfdanarson T,
Bergsland E, Berlin J, Halperin D, Chan J, Kulke M, Benson A,
Blaszkowsky L, et al: NCCN clinical practice guidelines in
oncology: Neuroendocrine and adrenal tumors. J Natl Compr Canc
Netw. 16:693–702. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Partelli S, Bartsch DK, Capdevila J, Chen
J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher
A, Ramage J, et al: Antibes consensus conference participants:
ENETS consensus guidelines for standard of care in neuroendocrine
tumours: Surgery for small intestinal and pancreatic neuroendocrine
tumours. Neuroendocrinology. 105:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Norton JA, Kivlen M, Li M, Schneider D,
Chuter T and Jensen RT: Morbidity and mortality of aggressive
resection in patients with advanced neuroendocrine tumors. Arch
Surg. 138:859–866. 2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Fernández-Cruz L, Blanco L, Cosa R and
Rendón H: Is laparoscopic resection adequate in patients with
neuroendocrine pancreatic tumors? World J Surg. 32:904–917.
2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Pavel M, O'Toole D, Costa F, Capdevila J,
Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, et
al: Vienna Consensus Conference participants: ENETS consensus
guidelines update for the management of distant metastatic disease
of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN)
and NEN of unknown primary site. Neuroendocrinology. 103:172–185.
2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Moug SJ, Leen E, Horgan PG and Imrie CW:
Radiofrequency ablation has a valuable therapeutic role in
metastatic VIPoma. Pancreatology. 6:155–159. 2006.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kennedy A, Bester L, Salem R, Sharma RA,
Parks RW and Ruszniewski P: NET-Liver-Metastases Consensus
Conference: Role of hepatic intra-arterial therapies in metastatic
neuroendocrine tumours (NET): Guidelines from the
NET-liver-metastases consensus conference. HPB (Oxford). 17:29–37.
2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Mazzaferro V, Pulvirenti A and Coppa J:
Neuroendocrine tumors metastatic to the liver: How to select
patients for liver transplantation? J Hepatol. 47:460–466.
2007.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Gedaly R, Daily MF, Davenport D, McHugh
PP, Koch A, Angulo P and Hundley JC: Liver transplantation for the
treatment of liver metastases from neuroendocrine tumours: An
analysis of the UNOS database. Arch Surg. 146:953–958.
2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Máthé Z, Tagkalos E, Paul A, Molmenti EP,
Kóbori L, Fouzas I, Beckebaum S and Sotiropoulos GC: Liver
transplantation for hepatic metastases of neuroendocrine pancreatic
tumors: A survival-based analysis. Transplantation. 91:575–582.
2011. View Article : Google Scholar
|
|
52
|
Moris D, Tsilimigras DI,
Ntanasis-Stathopoulos I, Beal EW, Felekouras E, Vernadakis S, Fung
JJ and Pawlik TM: Liver transplantation in patients with liver
metastases from neuroendocrine tumors: A systematic review.
Surgery. 162:525–536. 2017.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Tsilimigras DI, Ntanasis-Stathopoulos I,
Kostakis ID, Moris D, Schizas D, Cloyd JM and Pawlik TM: Is
resection of primary midgut neuroendocrine tumors in patients with
unresectable metastatic liver disease justified? A systematic
review and meta-analysis. J Gastrointest Surg. 23:1044–1054.
2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Guo J, Zhang Q, Bi X, Zhou J, Li Z, Huang
Z, Zhang Y, Li M, Chen X, Hu X, et al: Systematic review of
resecting primary tumor in MNETs patients with unresectable liver
metastases. Oncotarget. 8:17396–17405. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Yao JC, Shah MH, Ito T, Bohas CL, Wolin
EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG,
et al: Everolimus for advanced pancreatic neuroendocrine tumors. N
Engl J Med. 364:514–523. 2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Raymond E, Dahan L, Raoul JL, Bang YJ,
Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A,
et al: Sunitinib malate for the treatment of pancreatic
neuroendocrine tumors. N Engl J Med. 364:501–513. 2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
De Mestier L, Walter T, Brixi H,
Lombard-Bohas C and Cadiot G: Sunitinib achieved fast and sustained
control of VIPoma symptoms. Eur J Endocrinol. 172:K1–K3.
2015.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Phan AT, Halperin DM, Chan JA, Fogelman
DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC and Kulke MH:
Pazopanib and depot octreotide in advanced, well-differentiated
neuroendocrine tumours: A multicentre, single-group, phase 2 study.
Lancet Oncol. 16:695–703. 2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Hobday TJ, Qin R, Reidy-Lagunes D, Moore
MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H
and Erlichman C: Multicenter phase II trial of temsirolimus and
bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol.
33:1551–1556. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Akirov A, Larouche V, Alshehri S, Asa SL
and Ezzat S: Treatment options for pancreatic neuroendocrine
tumors. Cancers (Basel). 11(E828)2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Auernhammer CJ, Spitzweg C, Angele MK,
Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J,
Reincke M and Bartenstein P: Advanced neuroendocrine tumours of the
small intestine and pancreas: Clinical developments, controversies,
and future strategies. Lancet Diabetes Endocrinol. 6:404–415.
2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Strosberg J, El-Haddad G, Wolin E,
Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H,
et al: NETTER-1 trial investigators. Phase 3 trial of
177lu-dotatate for midgut neuroendocrine tumours. N Engl J Med.
376:125–135. 2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei
L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis
C, Kaltsas G, et al: ENETS consensus guidelines for the standards
of care in neuroendocrine neoplasia: Peptide receptor radionuclide
therapy with radiolabeled somatostatin analogues.
Neuroendocrinology. 105:295–309. 2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Brabander T, van der Zwan WA, Teunissen
JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen
GJH, Krenning EP and Kwekkeboom DJ: Long-term efficacy, survival,
and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with
gastroenteropancreatic and bronchial neuroendocrine tumours. Clin
Cancer Res. 23:4617–4624. 2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Zandee WT, Brabander T, Blažević A, Kam
BLR, Teunissen JJM, Feelders RA, Hofland J and de Herder WW:
Symptomatic and radiological response to 177Lu-DOTATATE for the
treatment of functioning pancreatic neuroendocrine tumors. J Clin
Endocrinol Metab. 104:1336–1344. 2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Adnan A and Basu S: Rare site primary soft
tissue neuroendocrine tumour with metastases and near-complete
resolution with 177Lu-DOTATATE: Documenting a promising
clinical application of peptide receptor radionuclide therapy. J
Nucl Med Technol. 119(227058): Aug 10, 2019 (Epub ahead of print).
View Article : Google Scholar
|
|
67
|
Jin XF, Spampatti MP, Spitzweg C and
Auernhammer CJ: Supportive therapy in gastroenteropancreatic
neuroendocrine tumors: Often forgotten but important. Rev Endocr
Metab Disord. 19:145–158. 2018.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Ataeinia B, Loberg C, Kravets H, Beheshti
M, von Mallek D, Mottaghy FM and Heinzel A: Successful palliative
peptide receptor radionuclide therapy for impending compression of
vena cava due to unresectable liver metastasis of neuroendocrine
tumor. EXCLI J. 18:273–276. 2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Hennrich U and Kopka K:
Lutathera®: The first FDA- and EMA-approved
radiopharmaceutical for peptide receptor radionuclide therapy.
Pharmaceuticals (Basel). 12(E114)2019.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Roland CL, Bian A, Mansour JC, Yopp AC,
Balch GC, Sharma R, Xie XJ and Schwarz RE: Survival impact of
malignant pancreatic neuroendocrine and islet cell neoplasm
phenotypes. J Surg Oncol. 105:595–600. 2012.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Loh HH and Tan F: Pancreatic vasoactive
intestinal peptide producing tumor (VIPoma): A case report and
literature review. Endokrinolojide Diyalog. 10:32–37. 2013.
|
|
72
|
Karim N, Zarzour A, Daw HA, Palaparty P,
Taftaf R, Shehata M and Taylor HC: Prolonged survival in a patient
with metastatic vasoactive intestinal peptide producing pancreatic
neuroendocrine tumors. J Clin Case Rep. 2(210)2012. View Article : Google Scholar
|
|
73
|
Soga J and Yakuwa Y: Vipoma/diarrheogenic
syndrome: A statistical evaluation of 241 reported cases. J Exp
Clin Cancer Res. 17:389–400. 1998.PubMed/NCBI
|
